e-learning
resources
London 2016
Wednesday, 07.09.2016
Airway pharmacology: drug targets and mode of action
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an ex vivo model of COPD exacerbation
Paola Rogliani (Rome, Italy), Paola Rogliani, Josuel Ora, Luigino Calzetta, Gabriella Lucà, Maria Gabriella Matera, Mario Cazzola
Source:
International Congress 2016 – Airway pharmacology: drug targets and mode of action
Session:
Airway pharmacology: drug targets and mode of action
Session type:
Poster Discussion
Number:
5062
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Paola Rogliani (Rome, Italy), Paola Rogliani, Josuel Ora, Luigino Calzetta, Gabriella Lucà, Maria Gabriella Matera, Mario Cazzola. Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Eur Respir J 2016; 48: Suppl. 60, 5062
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
The anti-proliferative effect of hydrogen sulfide upon human airway smooth muscle in COPD
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014
The novel compound Sul-121 inhibits inflammation in experimental models of chronic obstructive pulmonary disease
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Effect of roflumilast on airway remodeling in a murine model of chronic asthma
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Inhaled beta-agonist does not modify sympathetic activity in patients with COPD
Source: International Congress 2014 – Multidimensional analysis of respiratory problems
Year: 2014
Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation
Source: International Congress 2014 – Animal models: asthma, COPD and beyond
Year: 2014
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Development of a human COPD model-on-a-chip to mimic disease exacerbation (a small airway-on-a-chip model)
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma
Source: International Congress 2019 – Advances in asthma pharmacology
Year: 2019
Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD)
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014
Pharmacologic bronchodilation response to salbutamol in COPD patients
Source: International Congress 2014 – Predictors
Year: 2014
Monitoring catalase activity in COPD exacerbations
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Effect of different inhalation methods on the airway clearance in moderate and severe AECOPD
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma
Source: International Congress 2019 – Advances in asthma pharmacology
Year: 2019
Inhaled vilanterol trifenatate/fluticasone furoate increases maximum diaphragm contraction in severe COPD
Source: International Congress 2014 – Clinical physiology and respiratory muscles
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept